News

Filter

Current filters:

RebifGenzyme

1 to 9 of 18 results

Promising Ph II data for Genzyme/Bayer's alemtuzumab

27-10-2008

Findings from a mid-stage study suggest that leukemia drug Campath (alemtuzumab) can have a large and…

AlemtuzumabAspirinAvonexBayerBayerCampathGenzymeInterferon beta-1aMerck KGaARebif

Stock Commentary - New York - week to October 15, 2007

22-10-2007

NEW YORK: equities started the week to October 15 on a strong note, after a Federal Reserve Bank meeting…

AlemtuzumabAmgenAvonexBiogen IdecCampathGenzymeInterferon beta-1aNatalizumabPfizerRebifRituxanrituximabTysabri

Alemtuzumab cuts relapse risk in RRMS

22-10-2007

US biotechnology major Genzyme says that three-year data comparing alemtuzumab with Merck Serono's Rebif…

AlemtuzumabAspirinAvonexBayerBayerCampathFludaraFludarabineGenzymeInterferon beta-1aMerck KGaARebif

Genzyme/Bayer start Ph III alemtuzumab program

01-10-2007

USA-based Genzyme and Bayer Schering Pharma AG, of Germany say that the first patient has been treated…

AlemtuzumabAspirinAvonexBayerBayerCampathGenzymeInterferon beta-1aintravenous infusionMulti Vitamin ConcentrateRebif

Strong Ph II data on Genzyme/Bayer's MS drug

14-05-2007

US biotechnology major Genzyme and German drugmaker Bayer Healthcare reported positive interim data from…

AlemtuzumabAspirinAvonexBayerBayerCampathGenzymeInterferon beta-1aMerck KGaARebif

Biogen planning clinical trials of Amevive in Japan

11-02-2002

USA-based Biogen Inc has said it expects to commence clinical trials inJapan of Amevive (alfacept), for…

AlefaceptAmeviveAvonexGenzymeInterferon beta-1aRebif

1 to 9 of 18 results

COMPANY SPOTLIGHT

Menarini

Back to top